Premium
P3‐423: Efficacy of the 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's disease (OPTIMA) study: Prospective subgroup analysis by disease severity and time‐to‐meet decline
Author(s) -
Black Sandra,
Bakchine Serge,
Bellelli Giuseppe,
Molinuevo Jose Luis,
Downs Pamela,
Caputo Angelika,
Strohmaier Christine
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.2097
Subject(s) - rivastigmine , activities of daily living , medicine , clinical endpoint , randomized controlled trial , disease , dementia , physical therapy , donepezil
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom